CA2460345A1 - 2-aroylimidazole compounds for treating cancer - Google Patents

2-aroylimidazole compounds for treating cancer Download PDF

Info

Publication number
CA2460345A1
CA2460345A1 CA002460345A CA2460345A CA2460345A1 CA 2460345 A1 CA2460345 A1 CA 2460345A1 CA 002460345 A CA002460345 A CA 002460345A CA 2460345 A CA2460345 A CA 2460345A CA 2460345 A1 CA2460345 A1 CA 2460345A1
Authority
CA
Canada
Prior art keywords
substituted
alkyl
group
unsubstituted
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002460345A
Other languages
English (en)
French (fr)
Inventor
Keizo Koya
Lijun Sun
Mitsunori Ono
David James
Weiwen Ying
Shoujun Chen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Synta Phamaceuticals Corp
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2460345A1 publication Critical patent/CA2460345A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
CA002460345A 2001-09-13 2002-08-28 2-aroylimidazole compounds for treating cancer Abandoned CA2460345A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US32210501P 2001-09-13 2001-09-13
US60/322,105 2001-09-13
PCT/US2002/027514 WO2003022274A2 (en) 2001-09-13 2002-08-28 2-aroylimidazole compounds for treating cancer

Publications (1)

Publication Number Publication Date
CA2460345A1 true CA2460345A1 (en) 2003-03-20

Family

ID=23253436

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002460345A Abandoned CA2460345A1 (en) 2001-09-13 2002-08-28 2-aroylimidazole compounds for treating cancer

Country Status (6)

Country Link
US (2) US6743919B2 (enExample)
EP (1) EP1427413A2 (enExample)
JP (1) JP2005504789A (enExample)
AU (1) AU2002323475B2 (enExample)
CA (1) CA2460345A1 (enExample)
WO (1) WO2003022274A2 (enExample)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2460345A1 (en) * 2001-09-13 2003-03-20 Synta Pharmaceuticals Corp. 2-aroylimidazole compounds for treating cancer
ATE394373T1 (de) * 2002-02-12 2008-05-15 Wisconsin Alumni Res Found Synthese von indolthiazolverbindungen als liganden des ah-rezeptors
TW200503738A (en) * 2003-07-16 2005-02-01 Tzu Chi Buddhist General Hospital Method for extracting antineoplastic components from bupleurum scorzonerifolium
EP1697352B1 (en) * 2003-09-24 2012-06-27 Vertex Pharmceuticals Incorporated 4-azole substituted imidazole compositions useful as inhibitors or c-met receptor tyrosine kinase
JP4760712B2 (ja) * 2003-10-31 2011-08-31 オークランド ユニサーヴィスィズ リミテッド 新規ニトロフェニルマスタードおよびニトロフェニルアジリジンアルコールおよびそれらの対応するリン酸エステルおよびターゲットが決められた細胞毒性剤としてのそれらの使用
GB0403781D0 (en) * 2004-02-20 2004-03-24 Astrazeneca Ab Chemical compounds
BRPI0515482A (pt) 2004-09-20 2008-07-22 Xenon Pharmaceuticals Inc derivados heterocìclicos e seus usos como agentes terapêuticos
WO2006034341A2 (en) 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Pyridazine derivatives for inhibiting human stearoyl-coa-desaturase
MX2007003327A (es) 2004-09-20 2007-06-05 Xenon Pharmaceuticals Inc Derivados heterociclicos, y su uso como mediadores de estearoil-coa desaturasa.
AR051026A1 (es) 2004-09-20 2006-12-13 Xenon Pharmaceuticals Inc Derivados heterociclicos y su uso como inhibidores de la estearoil-coa desaturasa
CA2580855A1 (en) 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors
TW200626138A (en) 2004-09-20 2006-08-01 Xenon Pharmaceuticals Inc Heterocyclic derivatives and their use as therapeutic agents
US8071603B2 (en) 2004-09-20 2011-12-06 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-CoA desaturase inhibitors
WO2006128129A2 (en) * 2005-05-26 2006-11-30 Synta Pharmaceuticals Corp. Method for treating cancer
US8541457B2 (en) 2005-06-03 2013-09-24 Xenon Pharmaceuticals Inc. Aminothiazole derivatives as human stearoyl-CoA desaturase inhibitors
WO2007021825A2 (en) * 2005-08-09 2007-02-22 Tetralogic Pharmaceuticals Corporation Treatment of proliferative disorders
US20100256046A1 (en) * 2009-04-03 2010-10-07 Tetralogic Pharmaceuticals Corporation Treatment of proliferative disorders
US8883841B2 (en) * 2005-11-23 2014-11-11 The Board Of Regents Of The University Of Texas System Oncogenic ras-specific cytotoxic compound and methods of use thereof
EP1998766A2 (en) * 2005-12-16 2008-12-10 Ironwood Pharmaceuticals, Inc. Useful indole compounds
US7649098B2 (en) * 2006-02-24 2010-01-19 Lexicon Pharmaceuticals, Inc. Imidazole-based compounds, compositions comprising them and methods of their use
US7501438B2 (en) 2006-07-07 2009-03-10 Forest Laboratories Holdings Limited Pyridoimidazole derivatives
EP2120938A4 (en) * 2006-12-20 2010-12-08 Merck Sharp & Dohme IMIDAZOPYRIDINE ANALOGUE AS CB2 RECEPTOR MODULATORS FOR THE TREATMENT OF PAIN, RESPIRATORY AND NON-RESPIRATORY DISEASES
TW200920355A (en) * 2007-09-06 2009-05-16 Lexicon Pharmaceuticals Inc Compositions and methods for treating immunological and inflammatory diseases and disorders
ES2537624T3 (es) * 2007-10-26 2015-06-10 F. Hoffmann-La Roche Ag Derivados purina útiles como inhibidores de la quinasa PI3
CA2721851A1 (en) * 2008-05-30 2009-12-03 Genentech, Inc. Purine pi3k inhibitor compounds and methods of use
CA2730271A1 (en) 2008-07-07 2010-01-14 Xcovery Holding Company Llc Pi3k isoform selective inhibitors
US8173650B2 (en) 2009-05-27 2012-05-08 Genentech, Inc. Bicyclic pyrimidine PI3K inhibitor compounds selective for P110 delta, and methods of use
WO2011133520A1 (en) 2010-04-19 2011-10-27 Synta Pharmaceuticals Corp. Cancer therapy using a combination of a hsp90 inhibitory compounds and a egfr inhibitor
CA2802808A1 (en) 2010-07-14 2012-01-19 F. Hoffmann-La Roche Ag Purine compounds selective for pi3k p110 delta, and methods of use
EP2606031B1 (en) 2010-08-20 2017-09-27 Amira Pharmaceuticals, Inc. Autotaxin inhibitors and uses thereof
CA2820078C (en) 2010-12-16 2019-02-12 F. Hoffmann-La Roche Ag Tricyclic pi3k inhibitor compounds and methods of use
WO2012166415A1 (en) * 2011-05-27 2012-12-06 Amira Pharmaceuticals, Inc. Heterocyclic autotaxin inhibitors and uses thereof
WO2013067165A1 (en) 2011-11-02 2013-05-10 Synta Pharmaceuticals Corp. Combination therapy of hsp90 inhibitors with platinum-containing agents
JP2014532712A (ja) 2011-11-02 2014-12-08 シンタ ファーマシューティカルズ コーポレーション トポイソメラーゼｉ阻害剤とｈｓｐ９０阻害剤の組合せを使用する癌療法
WO2013074594A1 (en) 2011-11-14 2013-05-23 Synta Pharmaceuticals Corp. Combination therapy of hsp90 inhibitors with braf inhibitors
CN108841778B (zh) * 2018-04-28 2022-05-17 大连普瑞康生物技术有限公司 一种红豆杉细胞组织培养物
US12404265B2 (en) 2020-08-04 2025-09-02 Nura Bio, Inc. Substituted pyridine derivatives as SARM1 inhibitors
EP4214197A1 (en) 2020-09-16 2023-07-26 Nura Bio, Inc. Substituted pyridine derivatives as sarm1 inhibitors
KR20240041987A (ko) 2021-07-28 2024-04-01 누라 바이오, 인크. Sarm1 억제제로서 치환된 피리딘 유도체
WO2023064486A1 (en) * 2021-10-14 2023-04-20 Galileo Biosystems, Inc. Aryl hydrocarbon receptor (ahr) modulators and therapeutic uses thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0272810A3 (en) * 1986-11-26 1988-07-20 Harbor Branch Oceanographic Institution, Inc. Antitumor and antiviral alkaloids
US4866084A (en) * 1987-07-17 1989-09-12 Harbor Branch Oceanographic Institution, Inc. Topsentin compounds effective against viruses and certain tumors
US5290777A (en) 1993-02-24 1994-03-01 Regents Of The Univ. Of California Use for topsentin compounds and pharmaceutical compositions containing same
AU727608B2 (en) * 1995-10-03 2000-12-14 Scripps Research Institute, The CBI analogs of CC-1065 and the duocarmycins
EP0935463B1 (en) 1996-10-31 2004-01-21 Harbor Branch Oceanographic Institution, Inc. Use of anti-neurogenic inflammatory compounds and compositions
US6291501B1 (en) 1998-02-20 2001-09-18 Harbor Branch Oceanographic Institution, Inc. Compounds and methods of use for treatment of neurogenic inflammation
US6323233B1 (en) 1998-07-08 2001-11-27 Harbor Branch Oceanographic Institution Inc. Synthetic compounds for treatment of inflammation
CN1310906C (zh) * 1999-05-21 2007-04-18 肖斯公司 用作p38激酶抑制剂的吲哚类型的衍生物
CA2460345A1 (en) * 2001-09-13 2003-03-20 Synta Pharmaceuticals Corp. 2-aroylimidazole compounds for treating cancer

Also Published As

Publication number Publication date
WO2003022274A2 (en) 2003-03-20
WO2003022274A3 (en) 2003-07-10
JP2005504789A (ja) 2005-02-17
US6743919B2 (en) 2004-06-01
US7081466B2 (en) 2006-07-25
US20030096836A1 (en) 2003-05-22
EP1427413A2 (en) 2004-06-16
US20040186129A1 (en) 2004-09-23
AU2002323475B2 (en) 2006-09-28

Similar Documents

Publication Publication Date Title
CA2460345A1 (en) 2-aroylimidazole compounds for treating cancer
AU2002323475A1 (en) 2-aroylimidazole compounds for treating cancer
KR101760651B1 (ko) 피롤일 치환된 다이하이드로인돌 2 온 유도체, 그의 제조 방법 및 용도
BR122023006150B1 (pt) Compostos inibidores de hpk1, seu uso, e composição farmacêutica que os compreende
AU2007218966A1 (en) 2-(phenyl or heterocyclic) - 1h-phenanthro [9,10-d] imidazoles
WO2023207556A1 (zh) Prmt5-mta抑制剂
AU2016214492A1 (en) 2-phenyl-3H-imidazo[4,5-b]pyridine derivates useful as inhibitors of mammalian tyrosine kinase ROR1activity
AU2002323474B2 (en) 3-glyoxlylamideindoles for treating cancer
AU2002323474A1 (en) 3-glyoxlylamideindoles for treating cancer
EP1432709B1 (en) 1-glyoxlylamide indolizines for treating cancer
CN116583501A (zh) 用于治疗与lpa受体活性相关的病症的化合物和组合物
CN110407854B (zh) 新的四环化合物
KR102532912B1 (ko) 자궁 내막증 치료용 인돌의 신규 유도체
JP2006505577A (ja) ３位が複素環式基によって置換されたピリドインドロン誘導体、それらの製造法およびそれらの治療用途
HK40119859A (zh) 多激酶抑制剂、其组合物及使用方法
WO2023168908A1 (zh) 稠合的醌肟咪唑及其鎓衍生物与其制备和用途
HK1079507A (en) 1-glyoxylamide indolizines for treating cancer
TW202332441A (zh) 作為malt-1抑制劑之經取代雙環雜環
EP1598352A1 (en) 1-Glyoxylamide indolizines for treating cancer
HK1063322B (en) 1-glyoxylamide indolizines for treating cancer
US20100029599A1 (en) Indolylamides as modulators of the EP2 receptor

Legal Events

Date Code Title Description
FZDE Discontinued